Primary cutaneous lymphomas: a review with current treatment options

Blood Rev. 2003 Sep;17(3):131-42. doi: 10.1016/s0268-960x(03)00004-3.

Abstract

Primary cutaneous T- and B-cell lymphomas are a heterogenous group of diseases with varied clinical presentations and prognosis. The use of new molecular, histological, and clinical criteria have enhanced the recognition of primary cutaneous T- and B-cell lymphomas. Compared to their nodal counterpart they have a different clinical behavior and therefore require a different treatment approach. Independent predictive factors identified clinically, histologically, and by immunopheno- and immunogenotyping are essential to assess the appropriate treatment for each subtype. The European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Study Group provide a classification of cutaneous lymphomas taking into account of the histological and molecular features. Based on this classification we will provide a summary of the current medical literature in diagnosis, treatment, and prognosis for primary cutaneous lymphomas with emphasis on new treatment strategies.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Cytokines / therapeutic use
  • Europe
  • Humans
  • Immunotoxins / therapeutic use
  • Lymphoma, B-Cell / classification
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / pathology*
  • Lymphoma, T-Cell, Cutaneous / classification
  • Lymphoma, T-Cell, Cutaneous / drug therapy
  • Lymphoma, T-Cell, Cutaneous / pathology*
  • Male
  • Mycosis Fungoides / drug therapy
  • Mycosis Fungoides / pathology
  • Retinoids / therapeutic use
  • Sezary Syndrome / drug therapy
  • Sezary Syndrome / pathology
  • Skin Neoplasms / classification
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology*
  • World Health Organization

Substances

  • Antibodies, Monoclonal
  • Cytokines
  • Immunotoxins
  • Retinoids